MHRA agrees a paediatric investigation plan for retatrutide

The MHRA public register shows a decision agreeing a paediatric investigation plan (PIP) for retatrutide: PIP number MHRA-102112-PIP01-25, filed by Eli Lilly and Company Ltd, active substance retatrutide, therapeutic area obesity/overweight, decision type “P — decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferral(s).”